{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T23:47:54Z","timestamp":1776383274714,"version":"3.51.2"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T00:00:00Z","timestamp":1618876800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T00:00:00Z","timestamp":1618876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GE Healthcare Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The EU gadolinium-based contrast agents (GBCA) market has changed in recent years due to the European Medicines Agency decision to suspend the marketing authorisation of linear GBCA and the marketing authorisation of new generic macrocyclic GBCA. The study aims to understand the patterns of (GBCA) use, and to study the effectiveness and safety of GBCA in routine practice across Europe.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Prospective, cross-sectional, multicentre, observational study in patients undergoing contrast-enhanced magnetic resonance. Reported usage patterns included indication, referral and examination details. Assessment of effectiveness included changes in radiological diagnosis, diagnostic confidence and image quality. Safety data were collected by spontaneous patient adverse event (AE) reporting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>2118 patients were included from 8 centres across 5 European countries between December 2018 and November 2019. Clariscan, Dotarem (gadoteric acid), Gadovist (gadobutrol) and ProHance (gadoteridol) were utilised in 1513 (71.4%), 356 (16.8%), 237 (11.2%) and 12 (0.6%) patients, respectively. Most were performed in CNS-related indications (46.2%). Mean GBCA doses were 0.10\u00a0mmol\/kg body weight, except for Gadovist (mean 0.12\u00a0mmol\/kg). GBCA use increased confidence in diagnosis in 96.2% of examinations and resulted in a change in radiological diagnosis in 73.9% of patients. Image quality was considered excellent or good in 96.1% of patients and across all GBCA. Four patients reported AEs (0.19%), with only 1 (0.05%) considered serious.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This European study confirmed that GBCAs are used appropriately in Europe for a wide range of indications. The study demonstrated a significant increase in diagnostic confidence after GBCA use and confirmed the good safety profile of GBCAs, with comparable results for all agents used.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12880-021-00600-9","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T09:03:36Z","timestamp":1618909416000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Patterns of use, effectiveness and safety of gadolinium contrast agents: a European prospective cross-sectional multicentre observational study"],"prefix":"10.1186","volume":"21","author":[{"given":"Jarl \u00c5sbj\u00f8rn","family":"Jakobsen","sequence":"first","affiliation":[]},{"given":"Carlo Cosimo","family":"Quattrocchi","sequence":"additional","affiliation":[]},{"given":"Frank H. H.","family":"M\u00fcller","sequence":"additional","affiliation":[]},{"given":"Olivier","family":"Outteryck","sequence":"additional","affiliation":[]},{"given":"Andr\u00e9s","family":"Alc\u00e1zar","sequence":"additional","affiliation":[]},{"given":"Wolfgang","family":"Reith","sequence":"additional","affiliation":[]},{"given":"Patricia","family":"Fraga","sequence":"additional","affiliation":[]},{"given":"Valeria","family":"Panebianco","sequence":"additional","affiliation":[]},{"given":"Alexis","family":"Sampedro","sequence":"additional","affiliation":[]},{"given":"Radoslaw","family":"Pietura","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,4,20]]},"reference":[{"key":"600_CR1","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1148\/radiol.2018181151","volume":"289","author":"RJ McDonald","year":"2018","unstructured":"McDonald RJ, Levine D, Weinreb J, Kanal E, Davenport MS, Ellis JH, Jacobs PM, Lenkinski RE, Maravilla KR, Prince MR, Rowley HA, Tweedle MF, Kressel HY. Gadolinium retention: a research roadmap from the 2018 NIH\/ACR\/RSNA workshop on gadolinium chelates. Radiology. 2018;289:517\u201334.","journal-title":"Radiology"},{"key":"600_CR2","unstructured":"ACR Committee on Drugs and Contrast Media, ACR Manual on Contrast Media. Version 10.3. 2020. https:\/\/www.acr.org\/-\/media\/ACR\/Files\/Clinical-Resources\/Contrast_Media.pdf. Accessed 14 April 2020."},{"key":"600_CR3","unstructured":"EMA\u2019s final opinion confirms restrictions on use of linear gadolinium agents in body scans EMA\/457616\/2017. 2017. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/gadolinium-containing-contrast-agents. Accessed 2 Mar 2020."},{"key":"600_CR4","unstructured":"FDA identifies no harmful effects to date with brain retention of gadolinium-based contrast agents for MRIs. 2017. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-identifies-no-harmful-effects-date-brain-retention-gadolinium. Accessed 2 Mar 2020."},{"key":"600_CR5","unstructured":"Clariscan Summary of Product Characteristics. 2020. https:\/\/mri.cts-mrp.eu\/Human\/. Accessed 3 Mar 2020."},{"key":"600_CR6","unstructured":"Dotarem drug information. French Public Drug Database. 2020. http:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=69244971. Accessed 3 Mar 2020."},{"key":"600_CR7","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.3174\/ajnr.A5316","volume":"38","author":"KR Maravilla","year":"2017","unstructured":"Maravilla KR, San-Juan D, Kim SJ, Elizondo-Riojas G, Fink JR, Escobar W, Bag A, Roberts DR, Hao J, Pitrou C, Tsiouris AJ, Herskovits E, Fiebach JB. Comparison of gadoterate meglumine and gadobutrol in the MRI diagnosis of primary brain tumors: a double-blind randomized controlled intraindividual crossover study (the REMIND study). AJNR Am J Neuroradiol. 2017;38:1681\u20138.","journal-title":"AJNR Am J Neuroradiol"},{"key":"600_CR8","doi-asserted-by":"publisher","first-page":"e99079","DOI":"10.1371\/journal.pone.0099079","volume":"9","author":"J Hansmann","year":"2014","unstructured":"Hansmann J, Michaely HJ, Morelli JN, Luckscheiter A, Schoenberg SO, Attenberger UI. Enhancement characteristics and impact on image quality of two gadolinium chelates at equimolar doses for time-resolved 3-Tesla MR-angiography of the calf station. PLoS ONE. 2014;9:e99079.","journal-title":"PLoS ONE"},{"key":"600_CR9","first-page":"5","volume":"1","author":"M Abbas","year":"2016","unstructured":"Abbas M, Omer A, Hamad M. Adequacy of clinical information on radiology request cards from medical assessment unit, Clinical Audit. Nucl Med Biomed Imaging. 2016;1:5\u20136.","journal-title":"Nucl Med Biomed Imaging"},{"key":"600_CR10","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s10278-014-9751-7","volume":"28","author":"P Obara","year":"2015","unstructured":"Obara P, Sevenster M, Travis A, Qian Y, Westin C, Chang PJ. Evaluating the referring physician\u2019s clinical history and indication as a means for communicating chronic conditions that are pertinent at the point of radiologic interpretation. J Digit Imaging. 2015;28:272\u201382.","journal-title":"J Digit Imaging"},{"key":"600_CR11","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/01.rli.0000184756.66360.d3","volume":"40","author":"M Rohrer","year":"2005","unstructured":"Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005;40:715\u201324.","journal-title":"Invest Radiol"},{"key":"600_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/00004424-199502000-00002","volume":"30","author":"M Oudkerk","year":"1995","unstructured":"Oudkerk M, Sijens PE, Van Beek EJ, Kuijpers TJ. Safety and efficacy of dotarem (Gd-DOTA) versus magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system. Investig Radiol. 1995;30:75\u20138.","journal-title":"Investig Radiol"},{"key":"600_CR13","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.ejrad.2011.04.022","volume":"81","author":"M Maurer","year":"2012","unstructured":"Maurer M, Heine O, Wolf M, Durmus T, Wagner M, Hamm B. Tolerability and diagnostic value of gadoteric acid in the general population and in patients with risk factors: results in more than 84,000 patients. Eur J Radiol. 2012;81:885\u201390.","journal-title":"Eur J Radiol"},{"key":"600_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/01.rli.0000248893.01067.e5","volume":"42","author":"CU Herborn","year":"2007","unstructured":"Herborn CU, Honold E, Wolf M, Kemper J, Kinner S, Adam G, Barkhausen J. Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA). Invest Radiol. 2007;42:58\u201362.","journal-title":"Invest Radiol"},{"key":"600_CR15","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.ejrad.2016.10.013","volume":"85","author":"T Seithe","year":"2016","unstructured":"Seithe T, Braun J, Wolf M, Vahldiek J, Wolny D, Auer J, Pociej J, Heine O, Hamm B, de Bucourt M. Diagnostic efficacy and safety of gadoteric acid MR mammography in 1537 patients. Eur J Radiol. 2016;85:2281\u20137.","journal-title":"Eur J Radiol"},{"key":"600_CR16","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1007\/s00330-019-06171-2","volume":"29","author":"J Uhlig","year":"2019","unstructured":"Uhlig J, Lucke C, Vliegenthart R, Loewe C, Grothoff M, Schuster A, Lurz P, Jacquier A, Francone M, Zapf A, Schulke C, Daniel T, May MS, Bremerich J, Lotz J, Gutberlet M. ESCR MRCT registry contributors, acute adverse events in cardiac MR imaging with gadolinium-based contrast agents: results from the European Society of Cardiovascular Radiology (ESCR) MRCT Registry in 72,839 patients. Eur Radiol. 2019;29:3686\u201395.","journal-title":"Eur Radiol"},{"key":"600_CR17","doi-asserted-by":"publisher","first-page":"715","DOI":"10.2214\/AJR.17.18655","volume":"210","author":"F Sodagari","year":"2018","unstructured":"Sodagari F, Mozaffary A, Wood CG 3rd, Schmitz B, Miller FH, Yaghmai V. Reactions to both nonionic iodinated and gadolinium-based contrast media: incidence and clinical characteristics. AJR Am J Roentgenol. 2018;210:715\u20139.","journal-title":"AJR Am J Roentgenol"},{"key":"600_CR18","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1002\/jmri.25486","volume":"45","author":"P Soyer","year":"2017","unstructured":"Soyer P, Dohan A, Patkar D, Gottschalk A. Observational study on the safety profile of gadoterate meglumine in 35,499 patients: the SECURE study. J Magn Reson Imaging. 2017;45:988\u201397.","journal-title":"J Magn Reson Imaging"},{"key":"600_CR19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1148\/radiol.2016151066","volume":"281","author":"S Power","year":"2016","unstructured":"Power S, Talbot N, Kucharczyk W, Mandell DM. Allergic-like reactions to the MR imaging contrast agent gadobutrol: a prospective study of 32 991 consecutive injections. Radiology. 2016;281:72\u20137.","journal-title":"Radiology"},{"key":"600_CR20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1148\/radiol.10100906","volume":"259","author":"DE Morgan","year":"2011","unstructured":"Morgan DE, Spann JS, Lockhart ME, Winningham B, Bolus DN. Assessment of adverse reaction rates during gadoteridol-enhanced MR imaging in 28,078 patients. Radiology. 2011;259:109\u201316.","journal-title":"Radiology"},{"key":"600_CR21","first-page":"1","volume-title":"Side-effects of anti-inflammatory drugs, advances in inflammation research","author":"J Weber","year":"1984","unstructured":"Weber J. Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs. In: Rainsford KD, Velo GD, editors. Side-effects of anti-inflammatory drugs, advances in inflammation research. New York: Raven Press; 1984. p. 1\u20137."}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-021-00600-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-021-00600-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-021-00600-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T09:14:11Z","timestamp":1618910051000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedimaging.biomedcentral.com\/articles\/10.1186\/s12880-021-00600-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,20]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["600"],"URL":"https:\/\/doi.org\/10.1186\/s12880-021-00600-9","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,20]]},"assertion":[{"value":"23 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work has been carried out with ethics approvals from the following ethic committees in Rome (Comitato Etico dell\u2019Universit\u00e0 \u201cSapienza\u201d, Prot. 440\/19; Comitao Etico Universt\u00e0 Campus Bio-Medico di Roma, Prot. 33\/19 OSS), Ludwigshafen (Landes\u00e4rztekammer Rheinland-Pfalz, Ethik-Kommission, Antrags-Nr. 2018-13548), Homburg (\u00c4rztekammer des Saarlandes, Ethik-Kommission, Kenn-Nr. 222\/18), Lille (Comit\u00e9 de Protection des Personnes Nord Ouest IV, 18-11-05-71952, and Madrid (Comit\u00e9 \u00c9tico Fundaci\u00f3n Hospital Jim\u00e9nez D\u00edaz, ER_EO012-18). Approval in Lublin was not required, complying with national guidelines for research that exclude observational studies ().","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All eligible patients provided written informed consent prior to inclusion.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JAJ has been involved with GE Healthcare as a consultant. AS is a GE employee. The other authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"74"}}